Related Experiment Video
Updated: Jan 14, 2026
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
Bowel Urgency Severity Among Patients with Crohn's Disease or Ulcerative Colitis on Advanced Therapies: Real-World
James D Lewis1, Wai Man Maria Chan2, Richard E Moses2
1Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania.
Background And Aims:
Research on the impact of advanced therapies on bowel urgency severity in Crohn's disease (CD) and ulcerative colitis (UC) is limited. We assessed moderate-to-severe bowel urgency among patients with UC or CD at advanced therapy initiation, 6 months, and 12 months.
Methods:
Data from the Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease were used. Patients newly prescribed advanced therapies for CD or UC at enrollment, who completed the bowel urgency questionnaires and remained on the same advanced therapy at enrollment and at 6 months or 12 months, were included. Demographics, clinical data, and bowel urgency severity were summarized descriptively.
Results:
Overall, 532 patients with CD were included (332 on tumor necrosis factor inhibitors [TNFi]; 200 on non-TNFi). Moderate-to-severe bowel urgency was reported by 29.5% (enrollment) and 20.3% (12 months) in the TNFi group and 36.0% (enrollment) and 39.2% (12 months) in the non-TNFi group. Worsened urgency was noted in 21.7% (TNFi) and 19.4% (non-TNFi), while improvement was seen in 17.9% (TNFi) and 22.3% (non-TNFi). Among the 203 patients with UC (TNFi: 108; non-TNFi: 95), moderate-to-severe urgency was reported by 18.5% (enrollment) and 16.9% (12 months) in the TNFi group, and 34.7% (enrollment) and 32.1% (12 months) in the non-TNFi group. Worsened urgency was noted in 22.1% (TNFi) and 19.6% (non-TNFi), while improvement was seen in 16.9% (TNFi) and 17.9% (non-TNFi).
Conclusion:
Despite a year of advanced therapy, the percentage of patients with CD or UC experiencing bowel urgency remained similar.
Related Concept Videos
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...